| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.1 | 0.7 |
| Gross profit | -0.3 | -0.4 |
| Profit before tax | 0.6 | -1.5 |
| Net income | 0.6 | -1.5 |
| EPS (diluted, $ a share) | $-0.00 | $-0.00 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -79.0% |
|---|---|
| Gross margin | -201.7% |
| Operating margin | -387.0% |
Source
Read the filing ↗
10-Q filed with the SEC, CPMD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Cannapharmarx, Inc.: key numbers
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.